Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS Clinical Trials Group Protocol 273)

E. Richard Stiehm, Courtney V. Fletcher, Lynne M. Mofenson, Paul E. Palumbo, Minhee Kang, Terry Fenton, Christine V. Sapan, William A. Meyer, William T. Shearer, Elizabeth Hawkins, Mary Glenn Fowler, Pamela Bouquin, Lynette Purdue, Elaine M. Sloand, George J. Nemo, Diane Wara, Yvonne J. Bryson, Stuart E. Starr, Ann Petru, Sandra Burchett

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

The clinical, immunologic, and virologic effects and the pharmacokinetics of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin (HIVIG) were assessed in 30 HIV-infected children aged 2-11 years. All had moderately advanced disease with an immune complex- dissociated (ICD) p24 antigen >70 pg/mL and were on stable antiviral therapy. Three groups of 10 children received 6 monthly infusions of 200, 400, or 800 mg/kg of HIVIG, and serial immunologic and virologic assays were performed. HIVIG doses as high as 800 mg/kg were safe and well tolerated. The half-life of HIVIG, determined by serial p24 antibody titers, was 13-16 days, the volume of distribution was 102-113 mL/kg, and clearance was 5.6- 6.0 mL/kg/day. Plasma ICD p24 decreased during the infusions, but CD4 cell levels, plasma RNA copy number, cellular virus, immunoglobulin levels, and neutralizing antibody titers were minimally affected by the infusions. Clinical status did not change during the 6-month infusion and 3-month follow-up periods.

Original languageEnglish (US)
Pages (from-to)548-554
Number of pages7
JournalJournal of Infectious Diseases
Volume181
Issue number2
DOIs
StatePublished - 2000

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS Clinical Trials Group Protocol 273)'. Together they form a unique fingerprint.

  • Cite this

    Stiehm, E. R., Fletcher, C. V., Mofenson, L. M., Palumbo, P. E., Kang, M., Fenton, T., Sapan, C. V., Meyer, W. A., Shearer, W. T., Hawkins, E., Fowler, M. G., Bouquin, P., Purdue, L., Sloand, E. M., Nemo, G. J., Wara, D., Bryson, Y. J., Starr, S. E., Petru, A., & Burchett, S. (2000). Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS Clinical Trials Group Protocol 273). Journal of Infectious Diseases, 181(2), 548-554. https://doi.org/10.1086/315224